Takeda Receives US FDA Approval of FRUZAQLA™ (Fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda announced that the US FDA has approved FRUZAQLA™, an oral targeted therapy for adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.